[Jingtai Technology and Pierre Fabre Group have reached an AI drug research and development cooperation] On November 9, reporters learned from Jingtai Technology that the company has reached a cooperation agreement with the French pharmaceutical company Pierre Fabre Group. The two parties will jointly carry out multiple research and development projects in the field of oncology, using Jingtai Technology's "AI + robot" technology to design new small molecule drugs from scratch for undisclosed targets, and jointly promote the discovery of clinical drug candidates. The cooperation is expected to expand to dermatology, rare diseases and other fields in the future. According to the agreement, Jingtai Technology will be responsible for drug design and delivery, and Pierre Fabre Group will be responsible for compound screening and subsequent clinical and commercial development. The deal includes an down payment, multiple milestone payments and subsequent revenue sharing. (Reporter Lu Afeng)